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ABSTRACT 
Osteogenesis Imperfecta (OI) is an inherited bone fragility disorder most commonly associated with 
autosomal dominant mutations in the type I collagen genes. Autosomal recessive mutations in a 
number of genes have also been described, including the BMP1 gene that encodes the mammalian 
Tolloid (mTLD) and its shorter isoform bone morphogenic protein-1 (BMP1). To date, less than 20 
individuals with OI have been identified with BMP1 mutations, with skeletal phenotypes ranging from 
mild to severe and progressively deforming. In the majority of patients, bone fragility was associated 
with increased bone mineral density (BMD), however the full range of phenotypes associated with 
BMP1 remains unclear.  
Here we describe three children with mutations in BMP1 associated with a highly variable phenotype: a 
sibship homozygous for the c.2188delC mutation that affects only the shorter BMP1 isoform and a 
further patient who is compound heterozygous for a c.1293C>G nonsense mutation and a c.1148G>A 
missense mutation in the CUB1 domain. These individuals had recurrent fractures from early childhood, 
are hypermobile and have no evidence of dentinogenesis imperfecta. The homozygous siblings with OI 
had normal areal BMD by dual energy X ray absorptiometry whereas the third patient presented with a 
high bone mass phenotype. Intravenous bisphosphonate therapy was started in all patients, but 
discontinued in two patients and reduced in another due to concerns about increasing bone stiffness 
leading to chalk-stick fractures. Given the association of BMP1-related OI with very high bone material 
density, concerns remain whether anti-resorptive therapy is indicated in this ultra-rare form of OI. 
 
KEYWORDS:  Osteogenesis Imperfecta, bone fragility, BMP1, Bone morphogenic protein-1, high bone 
mass. 
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INTRODUCTION 
Osteogenesis Imperfecta (OI) is a rare inherited connective tissue disorder characterised by an 
increased tendency to fracture, often with minimal or no apparent trauma. Extra-skeletal features can 
include short stature, skin and joint hyper-extensibility, blue sclerae, deafness and dentinogenesis 
imperfecta.  Other features are bone pain, deformities, scoliosis and impaired mobility. 
Genetic characterisation of families affected with OI has shown that autosomal dominant 
mutations in the genes that encode the alpha chains of type I collagen (COL1A1 and COL1A2) can be 
identified in approximately 85-90% of affected individuals [Forlino and Marini 2016]. Mutations in a 
variety of other genes encoding proteins involved in type I collagen biosynthesis, bone cell 
differentiation, bone formation and bone remodelling are known to result in rare forms of autosomal 
recessive OI [Mendoza-Londono et al 2015]. A hallmark of OI at the tissue level is increased bone 
mineralisation density [Rauch and Glorieux 2004].  
Mutations in the BMP1 gene have been described in a small number of individuals with OI. The 
BMP1 gene (OMIM 112264) is alternatively transcribed to produce two proteins, Mammalian Tolloid 
(mTLD) and its shorter isoform bone morphogenic protein-1(BMP1). The BMP1/mTLD protein acts as 
an astacin metalloprotease whose functions include the proteolytic removal of the carboxyl-terminal 
propeptide from procollagen type I, II and III and the amino-terminal propeptide from types V and XI 
procollagen.  Studies in BMP1/mTLD deficient patients with OI have demonstrated delayed cleavage of 
type I collagen C-propeptide [Valencia et al 2014] and disorganization of type I/V collagen fibrils as well 
as impaired processing of the small leucine rich proteoglycan (SLRP) prodecorin [Syx et al 2015]. 
The OI phenotype of individuals with BMP1 mutations has been described as recurrent 
fractures, generalized bone deformity, osteopenia and Wormian bones  [Martinez-Glez et al 2012], and 
also as bone fragility associated with an increase in areal bone mineral density (BMD) as measured by 
dual-energy X-ray absorptiometry (DXA) [Asharani et al 2012], similar to mutations that affect the C-
propeptide cleavage site of type I collagen [Lindahl et al 2011]. At the tissue level, bone of one OI 
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patient with BMP1 mutations was found to be even more hypermineralized than in OI caused by 
collagen mutations [Hoyer-Kuhn et al 2013]. Patients with mutations affecting the C-propeptide 
cleavage site have also been reported to have bone mineral content that exceeds that of classical OI 
[Lindahl et al 2011] 
However, less than 20 indiviudals have been described with BMP1-related OI and therefore the 
full range of phenotypes associated with mutations in this gene is not well established.  Here we 
describe three patients that further expand the phenotypic spectrum of BMP1-related OI; a sibship 
presenting with OI and normal BMD and a further patient presenting with a high bone mass phenotype.  
MATERIALS AND METHODS 
Clinical Information and DNA extraction 
Clinical information was obtained from the patients’ medical records. The patients and their 
parents provided informed consent. Total genomic DNA was isolated from 2 to 5 ml peripheral blood 
taken from patients and parents using standard extraction methods.  
DNA sequencing and mutation analysis 
Targeted exome sequencing using SureSelect XT (Agilent Technologies) and Illumina MiSeq 
platform was used to sequence all coding regions and intron/exon boundaries of genes previously 
described in OI. The variants identified in the BMP1/mTLD gene were compared to reference 
sequences NM_001199.3 and NM_006129.4 and their pathogenicity assessed using Alamut Visual 
version 2.6 (Interactive Biosoftware, Rouen, France). 
RESULTS 
Clinical Characteristics 
Patient 1, the first child of consanguineous parents of Asian origin was born at 37 weeks 
gestation weighing 2.5kg. At 6 years of age, he was referred to the metabolic bone clinic for 
investigation having sustained 8-10 fractures in total including both tibiae, forearms, and a finger and 
toe. His first fracture, of the right wrist, occurred at age 12 months. He had no other significant medical 
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conditions, normal hearing and cognitive development. Due to non-union of a transverse right tibia 
fracture he had sustained at age 4 years, he mobilised using a wheelchair. On clinical examination 
there were no dysmorphic features. He had white sclerae, hypermobile fingers and no evidence of 
dentinogenesis imperfecta but severe dental decay requiring multiple tooth extractions. He had normal 
serum calcium and phosphate, alkaline phosphatase, parathyroid hormone and vitamin D levels. His 
lumbar spine BMD Z score, measured by DXA was -0.9. A diagnosis of OI was thought to be likely and 
intravenous pamidronate treatment (1.5mg/kg/day over 2 days 3 monthly) was commenced on the 
basis of persistent vertebral compression fracture at L1 (Figure 1) on a background of multiple long 
bone fractures. The non-union of the long-standing right tibial fracture required intramedullary nailing 
which allowed better mobility but never united subsequently. Further intramedullary nailing of left tibia 
and femur was required because of mid-shaft fractures. Pamidronate treatment was paused after 1 
year to promote healing of osteotomies. From age 9 years, he received zoledronic acid (0.05mg/kg/day 
single dose 6 monthly). His bone density increased in response to bisphosphonate therapy (Table I). 
However he continued to have long bone fractures, including a new vertebral fracture (T10), an oblique 
subtrochanteric left femur fracture age 11y (Figure 1) and a chalk-stick like mid-shaft femur fracture age 
13y, following 7.5 years on bisphosphonate therapy (Figure 2), which was subsequently discontinued.  
He is currently growing along the 10th centile for height and less than 4th centile for weight. His 
current head circumference is 52.2 cm (age 14 years, between -1 to -2 SD). 
His sister, Patient 2, was born at 36 weeks gestation weighing 2.42kg. She presented at 7 
months of age with bilateral ulnar and radial fractures following a fall down the stairs whilst in the arms 
of her older sister. Over the following 3 years she had three low impact tibia fractures necessitating right 
tibial rodding. Zoledronic acid infusions (0.035mg/kg/day single dose 4 monthly) were started at 3 years 
of age. On clinical examination, she had grey sclerae, hypermobile fingers and no evidence of 
dentinogenesis imperfecta. She had no other medical conditions, normal hearing and cognitive and 
gross motor development. Her height and weight are on the 3rd centile for age. Her bone profile and 
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vitamin D level at the time of diagnosis were normal. DXA scanning prior to treatment was not 
performed due to lack of paediatric bone mineral apparent density (BMAD) reference data and 
cooperation of children under 5 years [Crabtree et al 2014] . At the age of 5.2 years , her lumbar spine 
BMAD Z score was 0.9 and total body less head (TBLH) BMD Z score was 1.5, following 2 years of 
zoledronate treatment during which she sustained one further tibia fracture. Lateral vertebral 
assessment showed no evidence of vertebral compression fractures. Her head circumference currently 
is 47.5 cm (age 5.2 years, -2 SD). In light of her increasing BMAD and experience with her brother, 
zoledronate therapy was reduced in frequency to a once yearly infusion (0.05mg/kg).  
Patient 3, the only child of healthy non-consanguineous parents of North European origin. She 
was born following IVF treatment at 39 weeks gestation with a birth weight of 2.976 kg and her early 
developmental assessments were normal with the exception of gross motor development which was 
delayed; she sat up at 1 year of age and walked around 17 months of age. She was diagnosed with 
bilateral dislocated hips at 22 months of age for which she had surgery twice, and was immobilised in 
the hip spica. The patient’s first fracture, of the right fibula, occurred at the age of 2 years and 11 
months. She was reviewed at the age of 3yrs and 2 months, having sustained separate fractures of her 
right fibula and left tibia. Her lumbar spine (L1-4) BMD was 0.726 g/cm2 (BMAD Z score +4.2,calculated 
retrospectively ) and did not influence management because lateral thoracic and lumbar spine 
radiographs done at the same time did not show any vertebral deformity, osteopenia or clear 
radiological evidence of increased bone density. Her lower-limb fragility fractures were attributed to 
prolonged immobilisation in hip spica. She was subsequently seen in another centre having had further 
fractures, including a spiral fracture of the tibia and three metatarsal fractures in the left foot and was 
empirically treated with pamidronate at age 3¾ years (1mg/kg on three consecutive days, three 
monthly). She received 4 cycles (total dose 12 mg/kg) before treatment was discontinued as her long 
bones now appeared abnormally dense on radiographs, and she started to suffer apparent ‘chalk stick 
fractures’ of her tibiae & fibulae (Figure 3).  At the age of 5½ years, bone mineral density 
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measurements were undertaken using various imaging techniques (Table II). The girl’s distal radial total 
and trabecular volumetric BMD Z score, measured by peripheral computed tomography, were markedly 
elevated being +8.7 and +9.2 respectively. At the lumbar spine (LS), her BMAD Z score (+4.3), 
measured by DXA was elevated but surprisingly not the volumetric trabecular BMD Z score (+0.3) 
measured by QCT. This apparent discrepancy suggests that the trabecular compartment in the LS is 
less affected than that at the distal radius, however different reference data used to calculate Z scores 
by these two techniques in the presence of high cortical bone mass may be a contributing factor. 
Radiograph of the spine and lateral vertebral fracture assessment by DXA (Figure 3) did not reveal 
vertebral fractures. A provisional diagnosis of a mild form of osteopetrosis was suggested, however 
genetic testing for a panel of 21 genes, including CLCN7 and LRP5, was negative. She has continued 
to have long bone fractures; the most recent are ‘chalk-stick’ like mid-shaft fractures of the left tibia and 
fibula at age 7¾ years, 3 years after discontinuation of bisphosphonate therapy.  
On clinical examination at aged 7 years, she had white sclerae and normal teeth, hearing and 
spine.  She has a bossed forehead and mild left sided ptosis. She has generalised hypermobility with a 
Beighton score of 8/9 with soft, velvety and very stretchy skin.  
Identification of BMP1 mutations 
Mutations in the COL1A1 and COL1A2 genes were excluded in all 3 patients. Targeted exome 
sequencing for a panel of additional genes associated with OI revealed that patient 1 and 2 were 
homozygous for the previously described c. 2188dupC mutation [Syx et al 2015]. The parents were 
confirmed to be heterozygous carriers.  
Patient 3 was compound heterozygous for two novel mutations, a c.1293C>G;p.(Tyr431*) non-
sense mutation and a c.1148G>A;p.(Arg383Gln) missense mutation in the CUB1 domain of BMP1. 
Parental testing demonstrated that the c.1293C>G;p.(Tyr431*) was present in the mother and 
c.1148G>A;p.(Arg383Gln) in the father.  
DISCUSSION 
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To date the majority, but not all, of individuals described with BMP1-associated OI have 
presented with bone fragility associated with increased BMD although no clear genotype-phenotype 
correlation has yet emerged. 
The c.2188dupC identified in patients 1 and 2 is predicted to have different outcomes 
dependent on the gene transcript. In the shorter BMP1 transcript, this mutation would lead to the 
creation of an extended protein (p.Gln730Profs*294), whereas in the longer mTLD transcript this 
mutation is predicted to result in an intronic duplication (c.2108-605dupC). Two individuals who are 
compound heterozygous for this change and the recurring signal peptide mutation, p.(Gly12Arg), have 
previously been described [Syx et al 2015] . These individuals are reported to have a severe 
progressive form of OI. Patient 1 and patient 2 presented with a phenotype suggesting that the mutant 
protein may have residual C-propeptide cleavage activity and the c.2188dupC may therefore represent 
a relatively ‘mild’ mutation. 
The markedly increased bone mass and ‘chalk-stick’ pattern of long-bone fractures of patient 3 
initially suggested a diagnosis of osteopetrosis. To date, similar compound heterozygous changes that 
result in a ‘null’ allele and a mutation in a CUB domain have been associated with severe OI 
phenotypes. Interestingly, a patient with a c 925delC frameshift mutation and a p.(Gly498Arg) 
substitution in the CUB2 domain is reported to have severe rhizomelic deformities, short stature and to 
have sustained over 100 fractures [Syx et al 2015]. Unfortunately no data is available for the associated 
BMD in this patient but, in contrast to patient 3, extensive skeletal surveys showed generalized 
undermineralization of long bones.  
It remains unclear why some BMP1 mutations are associated with increased BMD and others 
with normal or reduced BMD. Areal BMD measurements provide a composite value for bone mass 
within a given area, and do not reflect tissue mineralisation density – the combination of increased bone 
material density with reduced bone mass (as is typical in OI) can give values for BMD that sit within the 
normal range for age in children.  However, this is clearly not the case for patient 3, where size 
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corrected LS BMD (BMAD) and distal radius volumetric BMD are elevated (table II). Mineral crystals in 
OI patients are known to be smaller, have high calcium content and are more densely packed than in 
normal bone. Tissue mineralisation density may be a reflection of the degree of matrix disorganisation; 
some of the highest values are in type VI OI, where patients have a severely disrupted lamellar 
structure [Land et al 2007]. The multiple potential effects on matrix organisation resulting from 
mutations in BMP1 could be similarly disruptive.  
Bone tissue analysis of trabecular and cortical bone from an individual homozygous for the 
BMP1 p.(Gly12Arg) signal peptide mutation demonstrated increased regions of unmineralised matrix at 
sites of new bone formation, possibly caused by a delay in matrix maturation necessary for 
mineralisation.  In contrast, hypermineralisation was observed at older bone sites in the same bone 
sample, hypothesised to result from an increase in matrix space caused by retention of the C-
propeptide in collagen fibrils which is subsequently filled by mineral crystals [Hoyer-Kuhn et al 2013].   
Functional studies in patients with BMP1 mutations have largely focused on C-propeptide 
cleavage activity. However, BMP1/mTLD  is also involved in processing of additional extra cellular 
matrix components, in particular the processing of the SLRP prodecorin by removal of the prodomain, 
which has  been shown to be delayed in patients with BMP1 mutations [Syx et al 2015]. Decorin is 
known to influence both collagen assembly and regulate matrix mineralization [Mochida et al 2009]. 
The CUB domains of BMP1/mTLD are essential for C-proteinase activity; thus, mutations in different 
CUB domains may also be contributing to the variation in mineralization seen in these patients through 
their interaction with SLRPs. Potentially, this may explain why our patients with the c.2188dup, where 
all the CUB domains are intact, did not present with a high bone mass phenotype.  
Intravenous bisphosphonate therapy was started in all patients, but discontinued in two patients 
and reduced in the younger sibling due to concerns about increasing bone stiffness contributing to 
occurrence of chalk-stick fractures. Whilst bisphosphonates are not known to increase bone material 
density or stiffness in OI caused by collagen gene mutations [Weber et al 2006], they impair bone 
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remodelling/repair and healing, possibly allow accumulation of microdamage [Chapurlat and Delmas 
2009]  and are linked to atypical fractures in adults [Shane et al 2014]. Given the very high bone 
material density associated with BMP1-related OI and the potential risk of causing delayed healing, 
increased stiffness, atypical fractures [Vasanwala et al 2016] or even iatrogenic osteopetrosis [Whyte et 
al 2003], concerns remain whether anti-resorptive therapy is indicated in this ultra-rare form of OI. 
Conclusion 
Our patients demonstrate that bone mass in BMP1-related OI is highly variable and that OI 
should be considered as a possibility in individuals presenting with high bone mass and a significant 
fracture history. In addition, careful consideration and monitoring of response to bisphosphonate 
therapy in these patients is recommended. As further mutations are identified the functional 
consequence of BMP1 mutations and COL1A1/COL1A2 mutations affecting the type I collagen C-
propeptide cleavage site will become clearer. 
 
Acknowledgement: We would like to thank the families for consenting to publish their data and Dr 
Nicola Crabtree for calculating the pre-treatment BMAD Z score for patient 3. 
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Figure legends 
 
Figure 1: Patient 1 X-rays A. Compression fracture at L1 at age 8.5 years. B. Left low impact sub-
trochanteric femur fracture at age 11y (after 4.5y on bisphosphonate therapy). 
  
Figure 2:  Patient 1 X-rays, age 13y: Left ‘chalk-stick’ mid-shaft femur fracture following a fall 
at school (after 7.5years on bisphosphonate therapy). Note the mild Erlenmeyer-shape 
deformity of distal femur with ‘bisphosphonate’ lines. 
 
Figure 3: Patient 3 X-rays.  A. ‘Chalk stick’ fractures through right mid-tibia & mid-fibula, 
with soft tissue swelling.  Note dense & thickened cortices. Three ‘Pamidronate lines’ are 
visible at proximal and distal tibial metaphyses. B. Lateral vertebral fracture assessment by 
DXA at 5.5 years of age. Note absence of vertebral compression fractures. 
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Table I Response in lumbar spine (LS) and total body less head (TBLH) bone density Z-scores (by 
DXA) during intravenous bisphosphonate therapy in patient 1. Treatment was paused at age 7 due to 
rodding surgery. 
Age in years 6 
Pre-
Treatment  
7 
Treatment 
paused 
8 
Treatment 
recommenced 
9 10 12 14 
LS BMD -0.9 -0.8 -1.1 -0.8 -0.4 0.3 0.3 
LS BMAD (L1 –L4) -0.6 -0.6 -0.6 0.4 1.3 2.1 1.8 
TBLH BMD NA -0.5 -1.7 -0.4 -0.8 0.3 -0.4 
LS BMD – lumbar spine bone mineral density, LS BMAD - Lumbar spine bone mineral apparent density, TBLH – total body less head 
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Table II: Volumetric Bone Mineral Density Z-scores of Patient 3 measured by peripheral quantitative 
computed tomography (distal radius), DXA (lumbar spine) and quantitative computer tomography 
(lumbar spine). Pamidronate was started at 3.8 years of age and she remained on treatment for 12 
months before identification of raised BMD led to treatment discontinuation  
Age in years 3.2 5.5 6.5 7 
Distal radial total volumetric 
BMD 
Not measured +8.7 +7.1 +7.2 
Distal radial trabecular 
volumetric BMD 
Not measured +9.2 +6.9 +6.6 
LS BMAD (L1 –L4) +4.2 +4.3 +3.1 +3.4 
LS volumetric trabecular 
BMD (L1 –L3) 
Not measured +0.35 Not measured Not measured 
BMD – Bone mineral density, LS – lumbar spine, BMAD - bone mineral apparent density 
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Figure 1: Patient 1 X-rays A. Compression fracture at L1 at age 8.5 years. B. Left low impact sub-
trochanteric femur fracture at age 11y (after 4.5y on bisphosphonate therapy).  
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Figure 2:  Patient 1 X-rays, age 13y: Left ‘chalk-stick’ mid-shaft femur fracture following a fall at school 
(after 7.5years on bisphosphonate therapy). Note the mild Erlenmeyer-shape deformity of distal femur with 
‘bisphosphonate’ lines.  
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Figure 3: Patient 3 X-rays.  A. ‘Chalk stick’ fractures through right mid-tibia & mid-fibula, with soft tissue 
swelling.  Note dense & thickened cortices. Three ‘Pamidronate lines’ are visible at proximal and distal tibial 
metaphyses. B. Lateral vertebral fracture assessment by DXA at 5.5 years of age. Note absence of vertebral 
compression fractures.  
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